Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 5/20 | 0.32 |
| ▸ | FSHR | P23945 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069155 | 0.84 | RET (0.38) | RETSMN1; SMN2TSHRFSHRRAB9A | |
| SCHEMBL20147469 | 0.82 | RET (0.38) | RETSMN1; SMN2TSHRFSHRRAB9A | |
| SCHEMBL20158494 | 0.77 | RET (0.34) | RETSMN1; SMN2KDM4E | |
| SCHEMBL25261345 | 0.73 | MGLL (0.48) | — | |
| SCHEMBL20771226 | 0.71 | HDAC1 (0.48) | SMN1; SMN2RAB9AHDAC1HDAC2KDM4E | |
| SCHEMBL20147484 | 0.69 | ALDH1A1 (0.36) | RETRAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL5196730 | 0.68 | HDAC3 (0.46) | SMN1; SMN2TSHRRAB9AHDAC1HDAC2 | |
| SCHEMBL18190864 | 0.67 | SLC18A2 (0.40) | SMN1; SMN2TSHRRAB9AGHSRKDM4E | |
| SCHEMBL8592404 | 0.67 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRKDM4EALDH1A1MAPT | |
| SCHEMBL20147917 | 0.67 | ALDH1A1 (0.35) | RETSMN1; SMN2RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885SMN1; SMN2 646/4885TSHR 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.